The cerivastatin withdrawal crisis: A "post-mortem" analysis

Health Policy

Volumn 69, Issue 2, 2004, Pages 151-157

  Maggini, Marina ^a   Raschetti, Roberto ^a   Traversa, Giuseppe ^a   Bianchi, Clara ^a   Caffari, Bruno ^a   Da Cas, Roberto ^a   Panei, Pietro ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cerivastatin; Risk communication; Statin use

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PRAVASTATIN; SIMVASTATIN;

ARTICLE; AUTOPSY; CONTROLLED STUDY; DRUG MARKETING; DRUG WITHDRAWAL; HUMAN; ITALY; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRESCRIPTION; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR;

AGED; DRUG UTILIZATION; FEMALE; HEALTH SERVICES RESEARCH; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; ITALY; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PYRIDINES; RHABDOMYOLYSIS; RISK ASSESSMENT;

EID: 2942726062     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2004.04.001     Document Type: Article

References (17)

1. Ucar M, Mjörndal T Dahlqvist. HMG-CoA reductase inhibitors and myotoxicity. Drug Safety 2000; 22(6):441-57.
2. Shek A., Ferril M.J. Statin-fibrate combination therapy. Annals of Pharmacotherapy. 35:2001;908-917
3. Thompson P.D., Clarkson P., Karas R.H. Statin-associated myopathy. JAMA. 289(13):2003;1681-1688
4. Staffa J.A., Chang J., Green L. Cerivastatin and reports of fatal rhabdomyolysis. NEJM. 346(7):2002;539-540
5. Uppsala Monitoring Centre (WHO collaborating centre for international drug monitoring). Expecting the worst. Anticipating, preventing and managing medicinal product crises. Sweden; Uppsala: 2003. Available at: www.WHO-UMC.org.
6. Osservatorio nazionale sull'impiego dei medicinali. L'uso dei farmaci in Italia-Rapporto nazionale anno 2000. Luglio; Roma: 2001. Available at: www.ministerosalute.it/medicinali/osmed/osmed.jsp.
7. Osservatorio nazionale sull'impiego dei medicinali. L'uso dei farmaci in Italia-Rapporto nazionale anno 2001. Luglio; Roma: 2002. Available at: www.ministerosalute.it/medicinali/osmed/osmed.jsp.
8. Anonymous. Guidelines for ATC classification and DDD assignement. WHO collaborating centre for drug statistics. 1st ed. Oslo;1996.
9. Raschetti R., Maggini M., Popoli P. Time trends in the coprescribing of Cisapride and contraindicated drugs in Umbria, Italy. JAMA. 285:2001;1840-1841
10. Raschetti R., Santuccio C., Sabatini V., et al. Analisi delle segnalazioni spontanee di sospette reazioni avverse da farmaci. Italia-2001. Bollettino d'informazione sui Farmaci. 5:2002;8-18. Available at: www.ministerosalute.it/medicinali/normativa/sezNormativa.jsp?label=bol
11. Traversa G., Maggini M., Menniti-Ippolito F., et al. For the Italian Study Group for the Di Bella multitherapy trials. The unconventional Di Bella cancer treatment: a reflection on the Italian experience. Cancer. 86:1999;1903-1911
12. Guillebaud J. Advising women on which pill to take. BMJ. 311:1995;1111-1112
13. Martin R.M., Hilton S.R., Kerry S.M. The impact of the October 1995 "pill scare" on oral contraceptive use in the United Kingdom: analysis of a general practice automated database. Family Practice. 14(4):1997;279-284
14. Dillner L. Pill scare linked to rise in abortions. BMJ. 312:1996;996
15. Mantel-Teeuwisse A.K., Klungel O.H., Egberts T.C.G., Verschuren W.M.M., Porsius A.J., de Boer A. Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin. Drug Safety. 27(1):2004;63-70
16. Schiff G.D., Keehr L.M., Sai T.T., Bult J. High rates of adverse effects and patient unawareness of withdrawn lipid-lowering drug combination in a public hospital clinic. Pharmacoepidemiol Drug Safety. 11:2002;643-645
17. Uppsala Monitoring Centre, WHO collaborating centre for international drug monitoring. Dialogue in Pharmacovigilance. More effective communication. Sweden; Uppsala: 2002. Available at: www.WHO-UMC.org.